Peapod Lane Capital LLC boosted its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 19.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 571,110 shares of the medical instruments supplier's stock after acquiring an additional 91,787 shares during the period. OraSure Technologies comprises about 2.2% of Peapod Lane Capital LLC's investment portfolio, making the stock its 19th biggest holding. Peapod Lane Capital LLC owned about 0.74% of OraSure Technologies worth $1,925,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently made changes to their positions in OSUR. US Bancorp DE increased its stake in shares of OraSure Technologies by 310.4% in the fourth quarter. US Bancorp DE now owns 19,433 shares of the medical instruments supplier's stock valued at $70,000 after purchasing an additional 14,698 shares during the period. Raymond James Financial Inc. acquired a new position in OraSure Technologies in the 4th quarter worth approximately $37,000. American Century Companies Inc. boosted its stake in OraSure Technologies by 11.4% in the 4th quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier's stock worth $8,468,000 after purchasing an additional 240,224 shares during the period. AXQ Capital LP acquired a new stake in shares of OraSure Technologies during the 4th quarter valued at $51,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of OraSure Technologies during the 4th quarter valued at $664,000. Institutional investors and hedge funds own 93.50% of the company's stock.
OraSure Technologies Price Performance
Shares of OSUR opened at $3.03 on Thursday. The company has a market capitalization of $226.64 million, a PE ratio of -7.21 and a beta of 0.45. OraSure Technologies, Inc. has a one year low of $2.36 and a one year high of $4.92. The company's fifty day moving average price is $2.84 and its 200 day moving average price is $3.28.
OraSure Technologies declared that its board has initiated a stock repurchase program on Monday, March 24th that authorizes the company to buyback $40.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 15.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its stock is undervalued.
Analyst Ratings Changes
A number of research firms have recently weighed in on OSUR. Evercore ISI restated an "in-line" rating and set a $3.00 price target on shares of OraSure Technologies in a report on Monday, May 19th. Wall Street Zen upgraded shares of OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th.
Get Our Latest Stock Report on OraSure Technologies
OraSure Technologies Company Profile
(
Free Report)
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Featured Stories
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OraSure Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.
While OraSure Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
